Nuvation Bio annual free cash flow
2020
2021
2022
2023
2024
2025
Nuvation Bio Free Cash Flow (FCF) History (NUVB)
Nuvation Bio reported −$173.8M in free cash flow for fiscal 2025, a decrease of $43.2M from the previous fiscal year, with a free cash flow margin of −276.27%.
View full Nuvation Bio company overviewNuvation Bio free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$173.8M | −$43.2M | — | −276.27% |
| 2024 | 2024-12-31 | −$130.6M | −$62.5M | — | −1658.52% |
| 2023 | 2023-12-31 | −$68.1M | $28.4M | — | — |
| 2022 | 2022-12-31 | −$96.5M | −$28.0M | — | — |
| 2021 | 2021-12-31 | −$68.5M | −$31.8M | — | — |
| 2020 | 2020-12-31 | −$36.7M | — | — | — |
Nuvation Bio quarterly free cash flow
Q1.20
Q2.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$43.2M | $5.1M | — | −136.41% |
| Q1 2026 | 2026-03-31 | $5.0M | $47.7M | — | +6.03% |
| Q4 2025 | 2025-12-31 | −$29.8M | $16.5M | — | −71.23% |
| Q3 2025 | 2025-09-30 | −$52.9M | −$21.7M | — | −403.21% |
| Q2 2025 | 2025-06-30 | −$48.4M | −$11.0M | — | −1000.60% |
| Q1 2025 | 2025-03-31 | −$42.7M | −$27.0M | — | −1384.53% |
| Q4 2024 | 2024-12-31 | −$46.3M | −$31.3M | — | −810.98% |
| Q3 2024 | 2024-09-30 | −$31.2M | −$15.1M | — | −4296.15% |
| Q2 2024 | 2024-06-30 | −$37.3M | −$19.8M | — | −2600.98% |
| Q1 2024 | 2024-03-31 | −$15.7M | $3.6M | — | — |
| Q4 2023 | 2023-12-31 | −$15.0M | $1.2M | — | — |
| Q3 2023 | 2023-09-30 | −$16.2M | $12.0M | — | — |
| Q2 2023 | 2023-06-30 | −$17.5M | $9.6M | — | — |
| Q1 2023 | 2023-03-31 | −$19.3M | $5.6M | — | — |
| Q4 2022 | 2022-12-31 | −$16.2M | $7.4M | — | — |
| Q3 2022 | 2022-09-30 | −$28.2M | −$15.0M | — | — |
| Q2 2022 | 2022-06-30 | −$27.1M | −$10.3M | — | — |
| Q1 2022 | 2022-03-31 | −$24.9M | −$10.1M | — | — |
| Q4 2021 | 2021-12-31 | −$23.6M | $661,000 | — | — |
| Q3 2021 | 2021-09-30 | −$13.2M | −$21.8M | — | — |
| Q2 2021 | 2021-06-30 | −$16.8M | — | — | — |
| Q1 2021 | 2021-03-31 | −$14.8M | — | — | — |
| Q2 2020 | 2020-06-30 | −$24.3M | — | — | — |
| Q1 2020 | 2020-03-31 | $8.6M | — | — | — |
Nuvation Bio free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$36.7M to −$173.8M, a net decrease of $137.1M. Nuvation Bio's latest reported quarter, Q2 2026, generated −$43.2M in free cash flow, an increase of $5.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Nuvation Bio filings at SEC.gov ↗